P/E ratio for Adaptimmune Therapeutics (ADAP)
P/E ratio as of May 2024 (TTM): -2.23
According to Adaptimmune Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.22959. At the end of 2022 the company had a P/E ratio of -1.43.
P/E ratio history for Adaptimmune Therapeutics from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.43 | -61.07% |
| 2021 | -3.68 | -34.52% |
| 2020 | -5.61 | 517.6% |
| 2019 | -0.9091 | -83.87% |
| 2018 | -5.64 | -28.32% |
| 2017 | -7.86 | 98.07% |
| 2016 | -3.97 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 uniQure QURE | -1.19 | -46.72% | 🇳🇱 Netherlands |
 Novavax NVAX | -0.6551 | -70.62% | 🇺🇸 USA |
 Exelixis EXEL | 78.1 | -3,601.98% | 🇺🇸 USA |
 Enzo Biochem ENZ | -1.11 | -50.38% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.